An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low… (NCT06082817) | Clinical Trial Compass
Not Yet RecruitingPhase 2
An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD
United States30 participantsStarted 2025-01-01
Plain-language summary
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Eligible subjects will receive 50 mg capsules of Kyzatrax® to be taken orally daily over a 3-month period. Multiple blood samples will be taken at baseline and on days 7, 28 and 56 to assess safety and pharmacokinetics of the testosterone. After the informed consent is signed and for up to 14 days after the last dose of study drug, participants will have serial blood samples collected in addition to other routine study procedures (e.g. vital signs measured, adverse events assessed, validated outcome scales completed).
Who can participate
Age range21 Years – 75 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant provides written informed consent and HIPAA authorization before any study procedures are conducted;
✓. Participant is female;
✓. Participant is aged 30 years or greater;
✓. Participant is menopausal either spontaneously (at least 12 months amenorrheic or 6 months amenorrheic and FSH \>40 IU/ml) or 6 weeks after bilateral salpingo-oophorectomy with or without hysterectomy.
✓. Participant has a body mass index (BMI) ≤ 34 kg/m2;
✓. Participant has a diagnosis of hypoactive sexual desire disorder;
✓. At screening, participant has a testosterone concentration \<30 ng/dL;
✓. Participant has a normal PAP smear within 6 months of first administration of study drug if participant has a cervix;
Exclusion criteria
✕. Participant has a hypersensitivity to testosterone, gelatin, glycerin, sorbitol, or titanium dioxide (the constituents of Kyzatrex capsule);
✕. Participant has received intramuscular testosterone injections, oral or transdermal testosterone within 4 weeks, or subcutaneous testosterone pellet within 6 months prior to the screening visit, or receives any form of testosterone other than study drug during this trial;
✕. Participant has documented or suspected breast cancer, history of heart attack or stroke;
✕. Participant has a clinically significant history of disease which could alter absorption, distribution, metabolism, or elimination, such as hepatic, renal, hematologic, gastrointestinal, respiratory, endocrine, or neurological disease;
✕. Participant has an EKG with an abnormality of clinical significance;
✕. Participant has an abnormal PAP smear if she has a cervix;
✕. Participant has any chronic medical condition or psychologic disorder that the Principal Investigator feels makes her ineligible for the study;
✕. Participant requires major surgery within 4 weeks before signing consent or at any time during the study;